Literature DB >> 6303648

Opiate receptors: enkephalins and endorphins.

A Grossman, V Clement-Jones.   

Abstract

Opiate receptors in the central nervous system may be classified according to pharmacological, behavioural, or binding studies. Classical mu-receptors probably have beta-endorphin as an endogenous ligand, and seem to be involved in the modulation of pain perception, low-frequency acupuncture analgesia, and the stimulation of prolactin, growth hormone and thyroid-stimulating hormone release. Met-enkephalin is likely to be an endogenous ligand for the delta-receptors, which predominate in the basal ganglia and limbic systems; such receptors may tonically inhibit the release of corticotrophin-releasing factor. It has been suggested that the newly-described kappa-receptors may inhibit the release of vasopressin and gonadotrophin-releasing factor; dynorphin may be their endogenous ligand. Endogenous opiates controlling cardiovascular and respiratory reflexes are likely to activate mu-receptors, while high-frequency acupuncture may alleviate the symptoms of opiate withdrawal by allowing an increase in Met-enkephalin to activate delta-receptors. In the periphery, beta-endorphin is concentrated in the corticotrophs of the anterior pituitary, and is cosecreted with ACTH and related peptides. Circulating Met-enkephalin originates in the gut, sympathetic nervous system and adrenal medulla. Met-enkephalin may also be extracted from carcinoid tumours and phaeochromocytomas. Elevations in circulating Met-enkephalin may occur in certain disease states with cardiovascular and psychiatric manifestations. However, manipulation of endogenous or exogenous opiates has as yet no certain place in any clinical situation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6303648     DOI: 10.1016/s0300-595x(83)80028-0

Source DB:  PubMed          Journal:  Clin Endocrinol Metab        ISSN: 0300-595X


  12 in total

1.  Plasma leucine enkephalin is increased in liver disease.

Authors:  J R Thornton; M S Losowsky
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

2.  Is ascites caused by impaired hepatic inactivation of blood borne endogenous opioid peptides?

Authors:  J R Thornton; H Dean; M S Losowsky
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

3.  Intracerebroventricular opiate infusion for refractory head and facial pain.

Authors:  Darrin J Lee; Gene G Gurkoff; Amir Goodarzi; J Paul Muizelaar; James E Boggan; Kiarash Shahlaie
Journal:  World J Clin Cases       Date:  2014-08-16       Impact factor: 1.337

Review 4.  Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy.

Authors:  Ángel Ortega; Juan Salazar; Néstor Galban; Milagros Rojas; Daniela Ariza; Mervin Chávez-Castillo; Manuel Nava; Manuel E Riaño-Garzón; Edgar Alexis Díaz-Camargo; Oscar Medina-Ortiz; Valmore Bermúdez
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

5.  Naloxone and the ventilatory response to exercise in man.

Authors:  C Griffis; R D Kaufman; S A Ward
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1986

6.  Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

7.  Effect of naltrexone treatment on the treadmill exercise-induced hormone release in amenorrheic women.

Authors:  G Botticelli; A Bacchi Modena; D Bresciani; P Villa; L Aguzzoli; P Florio; R E Nappi; F Petraglia; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

8.  Naltrexone effects on cortisol secretion in women and men in relation to a family history of alcoholism: studies from the Oklahoma Family Health Patterns Project.

Authors:  William R Lovallo; Andrea C King; Noha H Farag; Kristen H Sorocco; Andrew J Cohoon; Andrea S Vincent
Journal:  Psychoneuroendocrinology       Date:  2012-05-08       Impact factor: 4.905

9.  Endogenous kappa-opioid receptor systems inhibit hyperalgesia associated with localized peripheral inflammation.

Authors:  R J Schepers; Janet Lynn Mahoney; Brenda Jean Gehrke; Toni Shaun Shippenberg
Journal:  Pain       Date:  2008-03-19       Impact factor: 7.926

10.  The Effects of Pre-emptive Administration of Ketamine and norBNI on Pain Behavior, c-Fos, and Prodynorphin Protein Expression in the Rat Spinal Cord after Formalin-induced Pain Is Modulated by the DREAM Protein.

Authors:  Idris Long; Rapeah Suppian; Zalina Ismail
Journal:  Korean J Pain       Date:  2013-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.